Crisaborole: a dermatologic perspective
Crisaborole is a non-steroidal boron-containing topical phosphodiesterase-4 inhibitor that has been approved by the US-FDA for the treatment of atopic dermatitis in children (> 3 months of age) and adults. More recently, its efficacy has been outlined in the treatment of many other dermatoses, in...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Sociedade Portuguesa de Dermatologia e Venereologia
2025-04-01
|
| Series: | Revista da Sociedade Portuguesa de Dermatologia e Venereologia |
| Subjects: | |
| Online Access: | https://www.portuguesejournalofdermatology.com/frame_eng.php?id=241 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850102141066149888 |
|---|---|
| author | Aditya K. Bubna Vinayak Viplav |
| author_facet | Aditya K. Bubna Vinayak Viplav |
| author_sort | Aditya K. Bubna |
| collection | DOAJ |
| description | Crisaborole is a non-steroidal boron-containing topical phosphodiesterase-4 inhibitor that has been approved by the US-FDA for the treatment of atopic dermatitis in children (> 3 months of age) and adults. More recently, its efficacy has been outlined in the treatment of many other dermatoses, including vitiligo, psoriasis, morphea, seborrheic dermatitis, stasis dermatitis, and vulvar leukoplakia, to name a few. While crisaborole represents a valuable non-steroidal alternative in dermatological therapy, the primary limitation is its high cost compared to other topical agents. Nevertheless, despite this limitation, its use in recalcitrant cases can be worth considering.
|
| format | Article |
| id | doaj-art-b2bfc2eb44fe44168f47231a51ee3b37 |
| institution | DOAJ |
| issn | 2182-2395 2182-2409 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | Sociedade Portuguesa de Dermatologia e Venereologia |
| record_format | Article |
| series | Revista da Sociedade Portuguesa de Dermatologia e Venereologia |
| spelling | doaj-art-b2bfc2eb44fe44168f47231a51ee3b372025-08-20T02:39:49ZengSociedade Portuguesa de Dermatologia e VenereologiaRevista da Sociedade Portuguesa de Dermatologia e Venereologia2182-23952182-24092025-04-01832Crisaborole: a dermatologic perspectiveAditya K. Bubna0Vinayak Viplav1Department of Dermatology, Katihar Medical College, Karim Bagh, Bihar, IndiaDepartment of Dermatology, Katihar Medical College, Karim Bagh, Bihar, IndiaCrisaborole is a non-steroidal boron-containing topical phosphodiesterase-4 inhibitor that has been approved by the US-FDA for the treatment of atopic dermatitis in children (> 3 months of age) and adults. More recently, its efficacy has been outlined in the treatment of many other dermatoses, including vitiligo, psoriasis, morphea, seborrheic dermatitis, stasis dermatitis, and vulvar leukoplakia, to name a few. While crisaborole represents a valuable non-steroidal alternative in dermatological therapy, the primary limitation is its high cost compared to other topical agents. Nevertheless, despite this limitation, its use in recalcitrant cases can be worth considering. https://www.portuguesejournalofdermatology.com/frame_eng.php?id=241Crisaborole. Atopic dermatitis. Psoriasis. Vitiligo. Morphea. |
| spellingShingle | Aditya K. Bubna Vinayak Viplav Crisaborole: a dermatologic perspective Revista da Sociedade Portuguesa de Dermatologia e Venereologia Crisaborole. Atopic dermatitis. Psoriasis. Vitiligo. Morphea. |
| title | Crisaborole: a dermatologic perspective |
| title_full | Crisaborole: a dermatologic perspective |
| title_fullStr | Crisaborole: a dermatologic perspective |
| title_full_unstemmed | Crisaborole: a dermatologic perspective |
| title_short | Crisaborole: a dermatologic perspective |
| title_sort | crisaborole a dermatologic perspective |
| topic | Crisaborole. Atopic dermatitis. Psoriasis. Vitiligo. Morphea. |
| url | https://www.portuguesejournalofdermatology.com/frame_eng.php?id=241 |
| work_keys_str_mv | AT adityakbubna crisaboroleadermatologicperspective AT vinayakviplav crisaboroleadermatologicperspective |